(function(){var loadHandler=window['sl_{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}'];loadHandler&&loadHandler(131, '<div id="spr0_aef6f2f"><div id="spr1_aef6f2f" class="kern slide"><img id="img0_aef6f2f" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_aef6f2f" class="kern slide"><div id="spr3_aef6f2f" style="top:0.41px;"><div style="width:0px;"><span id="txt0_aef6f2f" data-width="407.312500" style="left:42.961px;top:0.058px;">The practice is currently changing …</span></div><div style="width:0px;"><span id="txt1_aef6f2f" data-width="98.683594" style="left:196.546px;top:33.658px;">In 2017 :</span></div></div><div id="spr4_aef6f2f" style="left:-0.001px;top:189.954px;"><div id="svg3_aef6f2f" style="top:36.352px;"><svg width="720" height="56" viewBox="0 0 720 56"><path fill="none" d="M0,0 h720 v55.739 h-720 Z"/></svg></div><div id="spr5_aef6f2f" style="top:36.352px;"><div style="width:0px;"><span id="txt2_aef6f2f" data-width="547.246094" style="left:87.012px;top:1.07px;">It has been substituted by Aromatase Inhibitors in post-menopause</span></div><div style="width:0px;"><span id="txt3_aef6f2f" data-width="516.630859" style="left:102.432px;top:25.07px;">Will soon be substituted by Fulvestrant in pre-menopause too ?</span></div></div><div id="svg4_aef6f2f" style="left:0px;top:0px;"><svg width="720" height="37" viewBox="0 0 720 37"><path fill="none" d="M0,0 h720 v36.352 h-720 Z"/></svg></div><div id="spr6_aef6f2f"><div style="width:0px;"><span id="txt4_aef6f2f" data-width="467.132813" style="left:128.202px;top:0.564px;">Tamoxifen is still widely used in pre-menopause</span></div></div></div><div id="spr7_aef6f2f" style="left:-0.001px;top:391.172px;"><div id="svg5_aef6f2f" style="top:36.391px;"><svg width="720" height="97" viewBox="0 0 720 97"><path fill="none" d="M0,0 h720 v96.937 h-720 Z"/></svg></div><div id="spr8_aef6f2f" style="top:36.391px;"><div style="width:0px;"><span id="txt5_aef6f2f" data-width="548.623047" style="left:86.66px;top:1.07px;">Till recently Fulvestrant was used for endocrine-resistant cases only</span></div><div style="width:0px;"><span id="txt6_aef6f2f" class="relpos" data-width="435.427734" style="left:26.58px;top:25.323px;">After FALCON study (2016) Fulvestrant can be used as the 1</span><span id="txt7_aef6f2f" class="relpos" data-width="8.712891" style="left:26.575px;top:26.298px;">st</span><span id="txt8_aef6f2f" class="relpos" data-width="225.043945" style="left:26.57px;top:25.323px;"> line treatment in advanced BC</span></div><div style="width:0px;"><span id="txt9_aef6f2f" data-width="543.128906" style="left:89.245px;top:46.923px;">CDK4/6 inhibitors are becoming a standard addition to AIs and Fulvestrant</span></div><div style="width:0px;"><span id="txt10_aef6f2f" data-width="637.497070" style="left:42.53px;top:68.523px;">Novel ER antagonists are under development to substitute Fulvestrant (discussed later)</span></div></div><div id="svg6_aef6f2f" style="left:0px;top:0px;"><svg width="721" height="37" viewBox="0 0 721 37"><path fill="none" d="M0,0 h720 v36.352 h-720 Z"/></svg></div><div id="spr9_aef6f2f"><div style="width:0px;"><span id="txt11_aef6f2f" data-width="707.519531" style="left:8.22px;top:0.564px;">Fulvestrant and CDK4/6-inhibitors are challenging the standard practices</span></div></div></div><div id="spr10_aef6f2f" style="top:84.813px;"><div id="svg7_aef6f2f" style="left:0px;top:0px;"><svg width="720" height="37" viewBox="0 0 720 37"><path fill="none" d="M0,0 h719.999 v36.352 h-719.999 Z"/></svg></div><div id="spr11_aef6f2f"><div style="width:0px;"><span id="txt12_aef6f2f" data-width="595.687500" style="left:63.515px;top:0.564px;">Aromatase inhibitors are still widely used in post-menopause</span></div></div><div id="svg8_aef6f2f" style="top:36.352px;"><svg width="720" height="56" viewBox="0 0 720 56"><path fill="none" d="M0,0 h720 v55.739 h-720 Z"/></svg></div><div id="spr12_aef6f2f" style="top:36.352px;"><div style="width:0px;"><span id="txt13_aef6f2f" data-width="689.101563" style="left:16.008px;top:1.07px;">Still the treatment of choice in early breast cancer (adjuvant + neo-adjuvant settings)</span></div><div style="width:0px;"><span id="txt14_aef6f2f" data-width="567.597656" style="left:77.112px;top:25.07px;">Challenged by Fulvestrant 500mg in the advanced (metastatic) setting</span></div></div></div><div id="spr13_aef6f2f" style="left:-0.001px;top:295.095px;"><div id="svg9_aef6f2f" style="left:0px;top:0px;"><svg width="721" height="37" viewBox="0 0 721 37"><path fill="none" d="M0,0 h720.001 v36.352 h-720.001 Z"/></svg></div><div id="spr14_aef6f2f"><div style="width:0px;"><span id="txt15_aef6f2f" data-width="666.222656" style="left:27.868px;top:0.564px;">Goserelin is optionally added to other treatments in pre-menopause</span></div></div><div id="svg10_aef6f2f" style="left:94.997px;top:36.044px;"><svg width="531" height="32" viewBox="0 0 531 32"><path fill="none" d="M0,0 h530.006 v31.505 h-530.006 Z"/></svg></div><div id="spr15_aef6f2f" style="left:94.997px;top:36.044px;"><div style="width:0px;"><span id="txt16_aef6f2f" data-width="512.314453" style="left:9.763px;top:1.07px;">Optional for tamoxifen, compulsory for AIs (in pre-menopause)</span></div></div></div><div id="svg11_aef6f2f" style="left:-2.25px;top:373.445px;"><svg width="725" height="5" viewBox="-2.25 -1.125 725 5"><g fill="#ff0000" stroke="none"><path stroke="#ff0000" stroke-width="2.25" stroke-linecap="butt" transform="translate(0,-374.569641)" d="M0,375.695 H720"/></g></svg></div></div></div>');})();